FindTrial
Sign In

An exploratory study of HER family single nucleotide polymorphisms in predicting the efficacy and adverse effects of pyrotinib in breast cancer patients

An exploratory study of HER family single nucleotide polymorphisms in predicting the efficacy and adverse effects of pyrotinib in breast cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037903
Enrollment
Unknown
Registered
2020-09-04
Start date
2020-09-07
Completion date
Unknown
Last updated
2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Case series:non

Sponsors

Shandong Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with breast cancer confirmed by histopathology; 2. Patients treated with pyrrolotinib maleate tablets; 3. patients aged 18-80 years old; 4. According to the response evaluation criteria in solid tumors (RECIST 1.1), patients with at least one measurable lesion; 5. Patients with an estimated survival time of more than 3 months; 6. Patients without contraindications.

Exclusion criteria

Exclusion criteria: 1. Combined with other malignant tumors; 2. Patients with short bowel syndrome or other diseases that seriously affect the absorption function of the small intestine are considered unsuitable for the study.

Design outcomes

Primary

MeasureTime frame
Progression Free Surviva;Diarrhea;—

Countries

China

Contacts

Public ContactHuihui Li

Shandong Cancer Hospital

15553103209@163.com+86 15553103209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026